Signal from the log
Astrocyte Pharmaceuticals
9,5 M$ · Series B · United States · Biotech
Astrocyte Pharmaceuticals, dans le Connecticut, développe AST-004, une molécule qui aide les astrocytes, les cellules de soutien du cerveau, à protéger les neurones après un choc. La société vise le premier médicament approuvé contre la commotion cérébrale, et un essai de phase 2 chez des joueurs de football australien a fini son recrutement.
Verified
Announced on , logged by the watch of 30 September 2026.
- Operation
- Funding round
- Announced amount
- 9,5 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by DeepWork Capital , with MintPharma Capital , Waterstar Capital , Dynagrow Capital , Angel Star Ventures
Provenance
Source prnewswire
Logged on 30 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.